所有图片(3)
About This Item
经验公式（希尔记法）:
C18H34ClN2O8PS
CAS号:
分子量:
504.96
EC 号:
MDL编号:
UNSPSC代码:
51102829
PubChem化学物质编号:
NACRES:
NA.76
推荐产品
质量水平
表单
solid
溶解性
DMSO: 224 mg/mL at 25 °C
抗生素抗菌谱
Gram-positive bacteria
作用机制
protein synthesis | interferes
储存温度
2-8°C
SMILES字符串
CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC([C@H](C)Cl)C2O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]2O
InChI
1S/C18H34ClN2O8PS/c1-5-6-10-7-11(21(3)8-10)17(24)20-12(9(2)19)15-13(22)14(23)16(18(28-15)31-4)29-30(25,26)27/h9-16,18,22-23H,5-8H2,1-4H3,(H,20,24)(H2,25,26,27)/t9-,10+,11-,12?,13+,14-,15?,16+,18+/m0/s1
InChI key
UFUVLHLTWXBHGZ-MWBQRTRKSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
Chemical structure: macrolide
应用
Clindamycin 2-phosphate is an aminoglycoside antibiotic that has been used to study the cytoxicity of antibiotics on human cell lines , Bacterial protein synthesis and peptide translation, and the inhibition of human Tyrosyl-DNA Phosphodiesterase .
生化/生理作用
Clindamycin 2-phosphate is a pharmacological tyrosyl-DNA phosphodiesterase (Tdp1) inhibitor. Clindamycin 2-phosphate can repair DNA topoisomerase I-DNA covalent complexes by hydrolyzing the tyrosyl-DNA bond. It inhibits protein synthesis in bacteria by binding the 50s ribosomal subunit. . Spectrum of Activity: Gram positive cocci and taxoplasma. Especially active against anaerobic bacteria.
Spectrum of Activity: Gram positive cocci and taxoplasma. Especially active against anaerobic bacteria.
Mode of Action: Inhibits protein synthesis in bacterial by binding the 50s ribosomal subunit.
Mode of Action: Inhibits protein synthesis in bacterial by binding the 50s ribosomal subunit.
其他说明
Antibacterial and antiprotozoal antibiotic of the licosamide class.
Keep container tightly closed in a dry and well-ventilated place.
警示用语：
Warning
危险分类
Acute Tox. 4 Oral - Eye Irrit. 2 - Lact. - Skin Sens. 1
储存分类代码
11 - Combustible Solids
WGK
WGK 3
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
法规信息
监管及禁止进口产品
Zhiyong Liao et al.
Molecular pharmacology, 70(1), 366-372 (2006-04-19)
DNA topoisomerase I (Top1) is the target of camptothecin, and novel Top1 inhibitors are in development as anticancer agents. Top1 inhibitors damage DNA by trapping covalent complexes between the Top1 catalytic tyrosine and the 3'-end of the broken DNA. Tyrosyl-DNA
Lawrence F Eichenfield et al.
Pediatric dermatology, 26(3), 257-261 (2009-08-27)
Treatments for mild to moderately severe acne usually combine retinoid and antimicrobial therapy. Recently, the US FDA approved the combination of 1.2% clindamycin (CLIN) and 0.025% tretinoin (RA) in a novel gel formulation for the treatment of mild to moderate
M Badawy Abdel-Naser et al.
Expert opinion on pharmacotherapy, 9(16), 2931-2937 (2008-10-22)
Clindamycin phosphate 1.2% together with tretinoin 0.025% as a gel (CTG) is a topical formulation of a fixed and stable combination approved by the FDA for the treatment of acne vulgaris in patients 12 years of age or older. The
Diane Thiboutot et al.
Journal of the American Academy of Dermatology, 59(5), 792-800 (2008-09-23)
We sought to evaluate efficacy, safety, and tolerability of a combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (clindamycin-BPO 2.5%) aqueous gel in moderate to severe acne vulgaris. A total of 2813 patients, aged 12 years or older, were
Vuk Uskoković et al.
Journal of biomedical materials research. Part A, 101(5), 1427-1436 (2012-11-02)
Osteomyelitis has been traditionally treated by the combination of long-term antibiotic therapies and surgical removal of diseased tissue. The multifunctional material was developed in this study with the aim to improve this therapeutic approach by: (a) enabling locally delivered and
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门